Stock price when the opinion was issued
With an aging population, whether an implant, knee replacement, heart surgery etc., any time they cut you open, they need to have the equipment in the operating room, but secondly you need that equipment sterilized, and this is what this company does. They did an acquisition of a UK company last year that outsources a lot of those services. There was some kind of integration hiccup and reporting hiccup. We get value creation as they take those out. Dividend yield of 1.5%. (Analysts’ price target is $80.50.)
Market leader in infection prevention and sterilization. Significant revenue from recurring sources. Repeat instrument sterilization and equipment maintenance. High-quality, defensive healthcare. Possible deregulation in US will benefit. Yield is only 1%, but grows 10-15%.
(Analysts’ price target is $252.00)